Symtomax Medical Cannabis

Symtomax is a licensed medical cannabis producer, with the largest outdoor cultivation site in Europe. The Portugal based cultivation facility site has a total of 105 Hectares, (1,005.000 m2) outdoor and 10,000 m2 indoor grow areas located in the Beja region of Portugal, focusing on providing safe and effective treatment options for worldwide pharmaceutical industries.

​​

Symtomax combines innovative horticultural techniques with an experienced team of award-winning growers, producing unique organic medical cannabis.

The securitized corporate loan note is to accelerate the development of the medical cannabis facility in Portugal (largest facility of its kind in Europe/Northern Hemisphere)

The cultivation land has been approved by the Portuguese regulatory body INFARMED for the cultivation of full spectrum

It is estimated that European countries combine to become the world's largest regulated medical cannabis market over the next five years

  • Fixed Return of 12% p.a., paid annualy over 24 month

  • Convertible Option: The investor will have the option to convert their principal capital  into equity, with 6 months’ notice prior tothe loan maturing.

  • Symtomax LDA will offer the debtors the ability to transfer each  EUR 20,000 of debt into 1share equivalent of the company.

  • Minimum Investment EUR/USD 25,000

RML Advisory

Fraumünsterstrasse 16

CH-8001 Zürich

hello@rml-advisory.ch

+41 44 521 10 56

© 2020 by RML Advisory

  • YouTube
  • Twitter
  • LinkedIn
  • Facebook
  • Instagram